

BEST AVAILABLE COPY

International Patent Class (Main): C08B-003/16; C09D-101/14
International Patent Class (Additional): A01N-025/10; B01J-032/00;
C11D-003/395

009951894

WPI Acc No: 1994-219607/199427

Use of bile salt-activated lipase in dietary supplement - to improve fat absorption or digestion., useful for eg compensating immature pancreatic development in premature infants

Patent Assignee: OKLAHOMA MEDICAL RES FOUND (OKLA-N); OKLAHOMA MED RES FOUND (OKLA-N)

Inventor: TANG J J N; WANG C

Number of Countries: 013 Number of Patents: 003

Patent Family:

Patent No	Kind	Date	Applicat No	Kind	Date	Week	
EP 605913	A1	19940713	EP 88310942	A	19881118	199427	B
			EP 93203480				
EP 605913	B1	20001025	EP 88310942	A	19881118	200055	
			EP 93203480				
DE 3856435	G	20001130	DE 3856435	A	19881118	200064	
			EP 93203480				

Priority Applications (No Type Date): US 87122410 A 19871119

Cited Patents: 2.Jnl.Ref; EP 21129; FR 2313916; GB 1571877; US 3256150; US 3991180

Patent Details:

Patent No	Kind	Lat	Pg	Main IPC	Filing Notes
EP 605913	A1	E	12	A61K-037/54	Related to application EP 88310942
					Designated States (Regional): AT BE CH DE ES FR GB GR IT LI LU NL SE
EP 605913	B1	E		A61K-047/28	Div ex application EP 88310942
					Div ex patent EP 317355
					Designated States (Regional): AT BE CH DE ES FR GB GR IT LI LU NL SE
DE 3856435	G			A61K-047/28	Based on patent EP 605913

Abstract (Basic): EP 605913 A

Use of an isolated mammalian bile salt-activated lipase (BAL) in the mfr. of a dietary supplement for improving the absorption or digestion of ingested fats is new, where the BAL is provided at a dose of at least 1 mg BAL per 2000 mg of ingested fat.

The BAL is derived from human, gorilla, dog or cat milk, or is a pancreatic carboxylesterase. The BAL may be encapsulated in an enteric coating. The dose is ca. 1 mg/200 mg fat. The BAL concn. in the supplement is more than 0.1 mg/ml.

USE - BAL-contg. dietary supplements may be used in infant formulas based on cow's milk or milk substitutes to compensate for immature pancreatic development in human (esp. premature infants. They may also be used to treat patients with pancreatic disease or trauma, and patients with genetic disorders associated with reduced fat absorption, e.g. cystic fibrosis.

In an example, Breast-fed kittens exhibited an average daily wt. gain of 13.27g over 5 days. The value for kittens fed with a commercial milk replacer was 6.46 g. The value for kittens fed with the milk replacer contg. 0.1 mg/ml human milk BAL was 11.38 g.

Dwg.O/O

Derwent Class: B04; D13; D16